HRP20171567T1 - Supstituirani 2-alkil-1-okso-n-fenil-3-heteroaril-1,2,3,4-tetrahidroizohinolin-4-karboksamidi za antimalarijske terapije - Google Patents
Supstituirani 2-alkil-1-okso-n-fenil-3-heteroaril-1,2,3,4-tetrahidroizohinolin-4-karboksamidi za antimalarijske terapije Download PDFInfo
- Publication number
- HRP20171567T1 HRP20171567T1 HRP20171567TT HRP20171567T HRP20171567T1 HR P20171567 T1 HRP20171567 T1 HR P20171567T1 HR P20171567T T HRP20171567T T HR P20171567TT HR P20171567 T HRP20171567 T HR P20171567T HR P20171567 T1 HRP20171567 T1 HR P20171567T1
- Authority
- HR
- Croatia
- Prior art keywords
- oxo
- tetrahydroisoquinoline
- carboxamide
- pyrazol
- isobutyl
- Prior art date
Links
- 239000003430 antimalarial agent Substances 0.000 title claims 3
- 230000000078 anti-malarial effect Effects 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- -1 4-isoxazolyl Chemical group 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 13
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 229910052801 chlorine Inorganic materials 0.000 claims 8
- 239000000460 chlorine Substances 0.000 claims 8
- 229910052731 fluorine Inorganic materials 0.000 claims 8
- KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 claims 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 5
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 5
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 3
- 229910052794 bromium Inorganic materials 0.000 claims 3
- 239000011737 fluorine Substances 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 125000006684 polyhaloalkyl group Polymers 0.000 claims 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 3
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 claims 2
- SARMGXPVOFNNNG-UHFFFAOYSA-N 1-[amino-(4-chloroanilino)methylidene]-2-propan-2-ylguanidine;hydron;chloride Chemical compound Cl.CC(C)N=C(N)N=C(N)NC1=CC=C(Cl)C=C1 SARMGXPVOFNNNG-UHFFFAOYSA-N 0.000 claims 2
- JICZMBWEYMJGOT-UHFFFAOYSA-N 1-oxo-3-(1h-pyrazol-4-yl)-2-(2,2,2-trifluoroethyl)-n-[3-(trifluoromethoxy)phenyl]-3,4-dihydroisoquinoline-4-carboxamide Chemical compound C12=CC=CC=C2C(=O)N(CC(F)(F)F)C(C2=CNN=C2)C1C(=O)NC1=CC=CC(OC(F)(F)F)=C1 JICZMBWEYMJGOT-UHFFFAOYSA-N 0.000 claims 2
- JYAPZSDAJFZFGP-UHFFFAOYSA-N 1-oxo-3-pyridin-3-yl-2-(2,2,2-trifluoroethyl)-n-[3-(trifluoromethoxy)phenyl]-3,4-dihydroisoquinoline-4-carboxamide Chemical compound C12=CC=CC=C2C(=O)N(CC(F)(F)F)C(C=2C=NC=CC=2)C1C(=O)NC1=CC=CC(OC(F)(F)F)=C1 JYAPZSDAJFZFGP-UHFFFAOYSA-N 0.000 claims 2
- QNFCJQQDWXNWTO-UHFFFAOYSA-N 2-(2-methylpropyl)-1-oxo-3-(1h-pyrazol-4-yl)-n-[3-(trifluoromethoxy)phenyl]-3,4-dihydroisoquinoline-4-carboxamide Chemical compound C12=CC=CC=C2C(=O)N(CC(C)C)C(C2=CNN=C2)C1C(=O)NC1=CC=CC(OC(F)(F)F)=C1 QNFCJQQDWXNWTO-UHFFFAOYSA-N 0.000 claims 2
- YUBRKYPPOSUWLM-UHFFFAOYSA-N 2-(2-methylpropyl)-1-oxo-3-pyridin-3-yl-n-[3-(trifluoromethoxy)phenyl]-3,4-dihydroisoquinoline-4-carboxamide Chemical compound C12=CC=CC=C2C(=O)N(CC(C)C)C(C=2C=NC=CC=2)C1C(=O)NC1=CC=CC(OC(F)(F)F)=C1 YUBRKYPPOSUWLM-UHFFFAOYSA-N 0.000 claims 2
- RRBGGBZMPKOJDM-UHFFFAOYSA-N 2-(2-methylpropyl)-3-(1-methylpyrazol-4-yl)-1-oxo-n-[3-(trifluoromethoxy)phenyl]-3,4-dihydroisoquinoline-4-carboxamide Chemical compound C12=CC=CC=C2C(=O)N(CC(C)C)C(C2=CN(C)N=C2)C1C(=O)NC1=CC=CC(OC(F)(F)F)=C1 RRBGGBZMPKOJDM-UHFFFAOYSA-N 0.000 claims 2
- JSIBLKONNPMZEN-UHFFFAOYSA-N 3-(1-methylpyrazol-4-yl)-1-oxo-2-(2,2,2-trifluoroethyl)-n-[3-(trifluoromethoxy)phenyl]-3,4-dihydroisoquinoline-4-carboxamide Chemical compound C1=NN(C)C=C1C1N(CC(F)(F)F)C(=O)C2=CC=CC=C2C1C(=O)NC1=CC=CC(OC(F)(F)F)=C1 JSIBLKONNPMZEN-UHFFFAOYSA-N 0.000 claims 2
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 claims 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 claims 2
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical group C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 claims 2
- 229960003677 chloroquine Drugs 0.000 claims 2
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 229960003722 doxycycline Drugs 0.000 claims 2
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 150000004677 hydrates Chemical class 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- DUJPTHOOGLZSBI-UHFFFAOYSA-N n-(3-chloro-5-cyanophenyl)-1-oxo-3-(1h-pyrazol-4-yl)-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinoline-4-carboxamide Chemical compound C12=CC=CC=C2C(=O)N(CC(F)(F)F)C(C2=CNN=C2)C1C(=O)NC1=CC(Cl)=CC(C#N)=C1 DUJPTHOOGLZSBI-UHFFFAOYSA-N 0.000 claims 2
- IVANNEBLWLVVTQ-UHFFFAOYSA-N n-(3-chloro-5-cyanophenyl)-1-oxo-3-pyridin-3-yl-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinoline-4-carboxamide Chemical compound C12=CC=CC=C2C(=O)N(CC(F)(F)F)C(C=2C=NC=CC=2)C1C(=O)NC1=CC(Cl)=CC(C#N)=C1 IVANNEBLWLVVTQ-UHFFFAOYSA-N 0.000 claims 2
- UJHYREHWQZFQPP-UHFFFAOYSA-N n-(3-chloro-5-cyanophenyl)-2-(2-methylpropyl)-1-oxo-3-(1h-pyrazol-4-yl)-3,4-dihydroisoquinoline-4-carboxamide Chemical compound C12=CC=CC=C2C(=O)N(CC(C)C)C(C2=CNN=C2)C1C(=O)NC1=CC(Cl)=CC(C#N)=C1 UJHYREHWQZFQPP-UHFFFAOYSA-N 0.000 claims 2
- WLFGHUIPZASVHI-UHFFFAOYSA-N n-(3-chloro-5-cyanophenyl)-2-(2-methylpropyl)-1-oxo-3-pyridin-3-yl-3,4-dihydroisoquinoline-4-carboxamide Chemical compound C12=CC=CC=C2C(=O)N(CC(C)C)C(C=2C=NC=CC=2)C1C(=O)NC1=CC(Cl)=CC(C#N)=C1 WLFGHUIPZASVHI-UHFFFAOYSA-N 0.000 claims 2
- JHXCYMUYHAUQCG-UHFFFAOYSA-N n-(3-chloro-5-cyanophenyl)-2-(2-methylpropyl)-3-(1-methylpyrazol-4-yl)-1-oxo-3,4-dihydroisoquinoline-4-carboxamide Chemical compound C12=CC=CC=C2C(=O)N(CC(C)C)C(C2=CN(C)N=C2)C1C(=O)NC1=CC(Cl)=CC(C#N)=C1 JHXCYMUYHAUQCG-UHFFFAOYSA-N 0.000 claims 2
- FWBCODRCMZEGNS-UHFFFAOYSA-N n-(3-chloro-5-cyanophenyl)-3-(1-methylpyrazol-4-yl)-1-oxo-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinoline-4-carboxamide Chemical compound C1=NN(C)C=C1C1N(CC(F)(F)F)C(=O)C2=CC=CC=C2C1C(=O)NC1=CC(Cl)=CC(C#N)=C1 FWBCODRCMZEGNS-UHFFFAOYSA-N 0.000 claims 2
- FLWXMOPNWVKIQC-UHFFFAOYSA-N n-(3-chloro-5-cyanophenyl)-7-fluoro-2-(2-methylpropyl)-3-(1-methylpyrazol-4-yl)-1-oxo-3,4-dihydroisoquinoline-4-carboxamide Chemical compound C12=CC=C(F)C=C2C(=O)N(CC(C)C)C(C2=CN(C)N=C2)C1C(=O)NC1=CC(Cl)=CC(C#N)=C1 FLWXMOPNWVKIQC-UHFFFAOYSA-N 0.000 claims 2
- ZKZZTOXSLJNDHR-UHFFFAOYSA-N n-(3-cyano-4-fluorophenyl)-1-oxo-3-(1h-pyrazol-4-yl)-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinoline-4-carboxamide Chemical compound C1=C(C#N)C(F)=CC=C1NC(=O)C1C2=CC=CC=C2C(=O)N(CC(F)(F)F)C1C1=CNN=C1 ZKZZTOXSLJNDHR-UHFFFAOYSA-N 0.000 claims 2
- VKCPFWKTFZAOTO-UHFFFAOYSA-N n-(3-cyano-4-fluorophenyl)-1-oxo-3-pyridin-3-yl-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinoline-4-carboxamide Chemical compound C1=C(C#N)C(F)=CC=C1NC(=O)C1C2=CC=CC=C2C(=O)N(CC(F)(F)F)C1C1=CC=CN=C1 VKCPFWKTFZAOTO-UHFFFAOYSA-N 0.000 claims 2
- SFUWBVVLCRMYSF-UHFFFAOYSA-N n-(3-cyano-4-fluorophenyl)-2-(2-methylpropyl)-1-oxo-3-(1,2-thiazol-4-yl)-3,4-dihydroisoquinoline-4-carboxamide Chemical compound C12=CC=CC=C2C(=O)N(CC(C)C)C(C2=CSN=C2)C1C(=O)NC1=CC=C(F)C(C#N)=C1 SFUWBVVLCRMYSF-UHFFFAOYSA-N 0.000 claims 2
- DNKSHWRXGBIWBR-UHFFFAOYSA-N n-(3-cyano-4-fluorophenyl)-2-(2-methylpropyl)-1-oxo-3-(1h-pyrazol-4-yl)-3,4-dihydroisoquinoline-4-carboxamide Chemical compound C12=CC=CC=C2C(=O)N(CC(C)C)C(C2=CNN=C2)C1C(=O)NC1=CC=C(F)C(C#N)=C1 DNKSHWRXGBIWBR-UHFFFAOYSA-N 0.000 claims 2
- KRXCWKMUHKEUAC-UHFFFAOYSA-N n-(3-cyano-4-fluorophenyl)-2-(2-methylpropyl)-1-oxo-3-pyridin-3-yl-3,4-dihydroisoquinoline-4-carboxamide Chemical compound C12=CC=CC=C2C(=O)N(CC(C)C)C(C=2C=NC=CC=2)C1C(=O)NC1=CC=C(F)C(C#N)=C1 KRXCWKMUHKEUAC-UHFFFAOYSA-N 0.000 claims 2
- IECIUAKUBYSJAC-UHFFFAOYSA-N n-(3-cyano-4-fluorophenyl)-2-(2-methylpropyl)-1-oxo-3-pyrimidin-5-yl-3,4-dihydroisoquinoline-4-carboxamide Chemical compound C12=CC=CC=C2C(=O)N(CC(C)C)C(C=2C=NC=NC=2)C1C(=O)NC1=CC=C(F)C(C#N)=C1 IECIUAKUBYSJAC-UHFFFAOYSA-N 0.000 claims 2
- SUINKIIVSSUICN-UHFFFAOYSA-N n-(3-cyano-4-fluorophenyl)-2-(2-methylpropyl)-3-(1-methylpyrazol-4-yl)-1-oxo-3,4-dihydroisoquinoline-4-carboxamide Chemical compound C12=CC=CC=C2C(=O)N(CC(C)C)C(C2=CN(C)N=C2)C1C(=O)NC1=CC=C(F)C(C#N)=C1 SUINKIIVSSUICN-UHFFFAOYSA-N 0.000 claims 2
- UQEVFULMKDMOKC-UHFFFAOYSA-N n-(3-cyano-4-fluorophenyl)-2-(cyclopropylmethyl)-1-oxo-3-pyridin-3-yl-3,4-dihydroisoquinoline-4-carboxamide Chemical compound C1=C(C#N)C(F)=CC=C1NC(=O)C1C2=CC=CC=C2C(=O)N(CC2CC2)C1C1=CC=CN=C1 UQEVFULMKDMOKC-UHFFFAOYSA-N 0.000 claims 2
- WIRJSBWWORVKOE-UHFFFAOYSA-N n-(3-cyano-4-fluorophenyl)-3-(1-methylpyrazol-4-yl)-1-oxo-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinoline-4-carboxamide Chemical compound C1=NN(C)C=C1C1N(CC(F)(F)F)C(=O)C2=CC=CC=C2C1C(=O)NC1=CC=C(F)C(C#N)=C1 WIRJSBWWORVKOE-UHFFFAOYSA-N 0.000 claims 2
- MWCWTZZSTDBJBT-UHFFFAOYSA-N n-(3-cyano-4-fluorophenyl)-7-fluoro-2-(2-methylpropyl)-3-(1-methylpyrazol-4-yl)-1-oxo-3,4-dihydroisoquinoline-4-carboxamide Chemical compound C12=CC=C(F)C=C2C(=O)N(CC(C)C)C(C2=CN(C)N=C2)C1C(=O)NC1=CC=C(F)C(C#N)=C1 MWCWTZZSTDBJBT-UHFFFAOYSA-N 0.000 claims 2
- OOBPRDMRPKYXJS-UHFFFAOYSA-N n-(3-cyano-4-fluorophenyl)-7-methoxy-2-(2-methylpropyl)-1-oxo-3-pyridin-3-yl-3,4-dihydroisoquinoline-4-carboxamide Chemical compound CC(C)CN1C(=O)C2=CC(OC)=CC=C2C(C(=O)NC=2C=C(C(F)=CC=2)C#N)C1C1=CC=CN=C1 OOBPRDMRPKYXJS-UHFFFAOYSA-N 0.000 claims 2
- MTYRHOGVFUQJMO-UHFFFAOYSA-N n-(3-cyano-5-fluorophenyl)-1-oxo-3-(1h-pyrazol-4-yl)-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinoline-4-carboxamide Chemical compound N#CC1=CC(F)=CC(NC(=O)C2C3=CC=CC=C3C(=O)N(CC(F)(F)F)C2C2=CNN=C2)=C1 MTYRHOGVFUQJMO-UHFFFAOYSA-N 0.000 claims 2
- CTVFGEOGXUKKDF-UHFFFAOYSA-N n-(3-cyano-5-fluorophenyl)-1-oxo-3-pyridin-3-yl-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinoline-4-carboxamide Chemical compound N#CC1=CC(F)=CC(NC(=O)C2C3=CC=CC=C3C(=O)N(CC(F)(F)F)C2C=2C=NC=CC=2)=C1 CTVFGEOGXUKKDF-UHFFFAOYSA-N 0.000 claims 2
- NZKLVVKLAPDEFK-UHFFFAOYSA-N n-(3-cyano-5-fluorophenyl)-2-(2-methylpropyl)-1-oxo-3-(1h-pyrazol-4-yl)-3,4-dihydroisoquinoline-4-carboxamide Chemical compound C12=CC=CC=C2C(=O)N(CC(C)C)C(C2=CNN=C2)C1C(=O)NC1=CC(F)=CC(C#N)=C1 NZKLVVKLAPDEFK-UHFFFAOYSA-N 0.000 claims 2
- UHTKJDSQXCHBPW-UHFFFAOYSA-N n-(3-cyano-5-fluorophenyl)-2-(2-methylpropyl)-1-oxo-3-pyridin-3-yl-3,4-dihydroisoquinoline-4-carboxamide Chemical compound C12=CC=CC=C2C(=O)N(CC(C)C)C(C=2C=NC=CC=2)C1C(=O)NC1=CC(F)=CC(C#N)=C1 UHTKJDSQXCHBPW-UHFFFAOYSA-N 0.000 claims 2
- SVQSZWWFPXNZKY-UHFFFAOYSA-N n-(3-cyano-5-fluorophenyl)-2-(2-methylpropyl)-3-(1-methylpyrazol-4-yl)-1-oxo-3,4-dihydroisoquinoline-4-carboxamide Chemical compound C12=CC=CC=C2C(=O)N(CC(C)C)C(C2=CN(C)N=C2)C1C(=O)NC1=CC(F)=CC(C#N)=C1 SVQSZWWFPXNZKY-UHFFFAOYSA-N 0.000 claims 2
- OWFHJWPIIYKLQN-UHFFFAOYSA-N n-(3-cyano-5-fluorophenyl)-3-(1-methylpyrazol-4-yl)-1-oxo-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinoline-4-carboxamide Chemical compound C1=NN(C)C=C1C1N(CC(F)(F)F)C(=O)C2=CC=CC=C2C1C(=O)NC1=CC(F)=CC(C#N)=C1 OWFHJWPIIYKLQN-UHFFFAOYSA-N 0.000 claims 2
- OZURUORUABOZTQ-UHFFFAOYSA-N n-(3-cyano-5-fluorophenyl)-6-fluoro-2-(2-methylpropyl)-3-(1-methylpyrazol-4-yl)-1-oxo-3,4-dihydroisoquinoline-4-carboxamide Chemical compound C12=CC(F)=CC=C2C(=O)N(CC(C)C)C(C2=CN(C)N=C2)C1C(=O)NC1=CC(F)=CC(C#N)=C1 OZURUORUABOZTQ-UHFFFAOYSA-N 0.000 claims 2
- WSNLIJDISCITEW-UHFFFAOYSA-N n-(3-cyano-5-fluorophenyl)-7-fluoro-3-(1-methylpyrazol-4-yl)-1-oxo-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinoline-4-carboxamide Chemical compound C1=NN(C)C=C1C1N(CC(F)(F)F)C(=O)C2=CC(F)=CC=C2C1C(=O)NC1=CC(F)=CC(C#N)=C1 WSNLIJDISCITEW-UHFFFAOYSA-N 0.000 claims 2
- WVKDLOUBIUKWEP-UHFFFAOYSA-N n-(3-cyanophenyl)-1-oxo-3-(1h-pyrazol-4-yl)-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinoline-4-carboxamide Chemical compound C12=CC=CC=C2C(=O)N(CC(F)(F)F)C(C2=CNN=C2)C1C(=O)NC1=CC=CC(C#N)=C1 WVKDLOUBIUKWEP-UHFFFAOYSA-N 0.000 claims 2
- XWJINLLYMWHJSS-UHFFFAOYSA-N n-(3-cyanophenyl)-1-oxo-3-pyridin-3-yl-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinoline-4-carboxamide Chemical compound C12=CC=CC=C2C(=O)N(CC(F)(F)F)C(C=2C=NC=CC=2)C1C(=O)NC1=CC=CC(C#N)=C1 XWJINLLYMWHJSS-UHFFFAOYSA-N 0.000 claims 2
- HBHDRUSNUINJCC-UHFFFAOYSA-N n-(3-cyanophenyl)-2-(2-methylpropyl)-1-oxo-3-(1h-pyrazol-4-yl)-3,4-dihydroisoquinoline-4-carboxamide Chemical compound C12=CC=CC=C2C(=O)N(CC(C)C)C(C2=CNN=C2)C1C(=O)NC1=CC=CC(C#N)=C1 HBHDRUSNUINJCC-UHFFFAOYSA-N 0.000 claims 2
- OQSRKNUAEQWIET-UHFFFAOYSA-N n-(3-cyanophenyl)-2-(2-methylpropyl)-1-oxo-3-pyridin-3-yl-3,4-dihydroisoquinoline-4-carboxamide Chemical compound C12=CC=CC=C2C(=O)N(CC(C)C)C(C=2C=NC=CC=2)C1C(=O)NC1=CC=CC(C#N)=C1 OQSRKNUAEQWIET-UHFFFAOYSA-N 0.000 claims 2
- LQICCRRRLHPGDM-UHFFFAOYSA-N n-(3-cyanophenyl)-2-(2-methylpropyl)-3-(1-methylpyrazol-4-yl)-1-oxo-3,4-dihydroisoquinoline-4-carboxamide Chemical compound C12=CC=CC=C2C(=O)N(CC(C)C)C(C2=CN(C)N=C2)C1C(=O)NC1=CC=CC(C#N)=C1 LQICCRRRLHPGDM-UHFFFAOYSA-N 0.000 claims 2
- HWPBLGMXZFBSRA-UHFFFAOYSA-N n-(3-cyanophenyl)-3-(1-methylpyrazol-4-yl)-1-oxo-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinoline-4-carboxamide Chemical compound C1=NN(C)C=C1C1N(CC(F)(F)F)C(=O)C2=CC=CC=C2C1C(=O)NC1=CC=CC(C#N)=C1 HWPBLGMXZFBSRA-UHFFFAOYSA-N 0.000 claims 2
- YSCJKBTWYQOCGY-UHFFFAOYSA-N n-(3-cyanophenyl)-6-fluoro-2-(2-methylpropyl)-3-(1-methylpyrazol-4-yl)-1-oxo-3,4-dihydroisoquinoline-4-carboxamide Chemical compound C12=CC(F)=CC=C2C(=O)N(CC(C)C)C(C2=CN(C)N=C2)C1C(=O)NC1=CC=CC(C#N)=C1 YSCJKBTWYQOCGY-UHFFFAOYSA-N 0.000 claims 2
- CLGVELMOYDGOFY-UHFFFAOYSA-N n-[3-fluoro-5-(trifluoromethoxy)phenyl]-1-oxo-3-(1h-pyrazol-4-yl)-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinoline-4-carboxamide Chemical compound FC(F)(F)OC1=CC(F)=CC(NC(=O)C2C3=CC=CC=C3C(=O)N(CC(F)(F)F)C2C2=CNN=C2)=C1 CLGVELMOYDGOFY-UHFFFAOYSA-N 0.000 claims 2
- JSSSNBFUTZJGKA-UHFFFAOYSA-N n-[3-fluoro-5-(trifluoromethoxy)phenyl]-1-oxo-3-pyridin-3-yl-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinoline-4-carboxamide Chemical compound FC(F)(F)OC1=CC(F)=CC(NC(=O)C2C3=CC=CC=C3C(=O)N(CC(F)(F)F)C2C=2C=NC=CC=2)=C1 JSSSNBFUTZJGKA-UHFFFAOYSA-N 0.000 claims 2
- GYGJAMIGQBAHKB-UHFFFAOYSA-N n-[3-fluoro-5-(trifluoromethoxy)phenyl]-2-(2-methylpropyl)-1-oxo-3-(1h-pyrazol-4-yl)-3,4-dihydroisoquinoline-4-carboxamide Chemical compound C12=CC=CC=C2C(=O)N(CC(C)C)C(C2=CNN=C2)C1C(=O)NC1=CC(F)=CC(OC(F)(F)F)=C1 GYGJAMIGQBAHKB-UHFFFAOYSA-N 0.000 claims 2
- YMMYZVALPCGYPU-UHFFFAOYSA-N n-[3-fluoro-5-(trifluoromethoxy)phenyl]-2-(2-methylpropyl)-1-oxo-3-pyridin-3-yl-3,4-dihydroisoquinoline-4-carboxamide Chemical compound C12=CC=CC=C2C(=O)N(CC(C)C)C(C=2C=NC=CC=2)C1C(=O)NC1=CC(F)=CC(OC(F)(F)F)=C1 YMMYZVALPCGYPU-UHFFFAOYSA-N 0.000 claims 2
- DLTLJZWKOYALBX-UHFFFAOYSA-N n-[3-fluoro-5-(trifluoromethoxy)phenyl]-2-(2-methylpropyl)-3-(1-methylpyrazol-4-yl)-1-oxo-3,4-dihydroisoquinoline-4-carboxamide Chemical compound C12=CC=CC=C2C(=O)N(CC(C)C)C(C2=CN(C)N=C2)C1C(=O)NC1=CC(F)=CC(OC(F)(F)F)=C1 DLTLJZWKOYALBX-UHFFFAOYSA-N 0.000 claims 2
- JJHLIXZXBNUQML-UHFFFAOYSA-N n-[3-fluoro-5-(trifluoromethoxy)phenyl]-3-(1-methylpyrazol-4-yl)-1-oxo-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinoline-4-carboxamide Chemical compound C1=NN(C)C=C1C1N(CC(F)(F)F)C(=O)C2=CC=CC=C2C1C(=O)NC1=CC(F)=CC(OC(F)(F)F)=C1 JJHLIXZXBNUQML-UHFFFAOYSA-N 0.000 claims 2
- RLFXBAYIHTZALY-UHFFFAOYSA-N n-[4-fluoro-3-(trifluoromethoxy)phenyl]-1-oxo-3-(1h-pyrazol-4-yl)-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinoline-4-carboxamide Chemical compound C1=C(OC(F)(F)F)C(F)=CC=C1NC(=O)C1C2=CC=CC=C2C(=O)N(CC(F)(F)F)C1C1=CNN=C1 RLFXBAYIHTZALY-UHFFFAOYSA-N 0.000 claims 2
- IKWRACQACAOENU-UHFFFAOYSA-N n-[4-fluoro-3-(trifluoromethoxy)phenyl]-1-oxo-3-pyridin-3-yl-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinoline-4-carboxamide Chemical compound C1=C(OC(F)(F)F)C(F)=CC=C1NC(=O)C1C2=CC=CC=C2C(=O)N(CC(F)(F)F)C1C1=CC=CN=C1 IKWRACQACAOENU-UHFFFAOYSA-N 0.000 claims 2
- WEBUSKBEDKNZDO-UHFFFAOYSA-N n-[4-fluoro-3-(trifluoromethoxy)phenyl]-2-(2-methylpropyl)-1-oxo-3-(1h-pyrazol-4-yl)-3,4-dihydroisoquinoline-4-carboxamide Chemical compound C12=CC=CC=C2C(=O)N(CC(C)C)C(C2=CNN=C2)C1C(=O)NC1=CC=C(F)C(OC(F)(F)F)=C1 WEBUSKBEDKNZDO-UHFFFAOYSA-N 0.000 claims 2
- VDHYXQOSBKVCPK-UHFFFAOYSA-N n-[4-fluoro-3-(trifluoromethoxy)phenyl]-2-(2-methylpropyl)-1-oxo-3-pyridin-3-yl-3,4-dihydroisoquinoline-4-carboxamide Chemical compound C12=CC=CC=C2C(=O)N(CC(C)C)C(C=2C=NC=CC=2)C1C(=O)NC1=CC=C(F)C(OC(F)(F)F)=C1 VDHYXQOSBKVCPK-UHFFFAOYSA-N 0.000 claims 2
- NHPKUKWISBKSTP-UHFFFAOYSA-N n-[4-fluoro-3-(trifluoromethoxy)phenyl]-2-(2-methylpropyl)-3-(1-methylpyrazol-4-yl)-1-oxo-3,4-dihydroisoquinoline-4-carboxamide Chemical compound C12=CC=CC=C2C(=O)N(CC(C)C)C(C2=CN(C)N=C2)C1C(=O)NC1=CC=C(F)C(OC(F)(F)F)=C1 NHPKUKWISBKSTP-UHFFFAOYSA-N 0.000 claims 2
- MCXVJAKEYWVFBT-UHFFFAOYSA-N n-[4-fluoro-3-(trifluoromethoxy)phenyl]-3-(1-methylpyrazol-4-yl)-1-oxo-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinoline-4-carboxamide Chemical compound C1=NN(C)C=C1C1N(CC(F)(F)F)C(=O)C2=CC=CC=C2C1C(=O)NC1=CC=C(F)C(OC(F)(F)F)=C1 MCXVJAKEYWVFBT-UHFFFAOYSA-N 0.000 claims 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 claims 2
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- XEEQGYMUWCZPDN-DOMZBBRYSA-N (-)-(11S,2'R)-erythro-mefloquine Chemical compound C([C@@H]1[C@@H](O)C=2C3=CC=CC(=C3N=C(C=2)C(F)(F)F)C(F)(F)F)CCCN1 XEEQGYMUWCZPDN-DOMZBBRYSA-N 0.000 claims 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
- LASDGSRKRVGQHF-UHFFFAOYSA-N 1-oxo-3-(1h-pyrazol-4-yl)-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinoline-4-carboxylic acid Chemical compound FC(F)(F)CN1C(=O)C2=CC=CC=C2C(C(=O)O)C1C=1C=NNC=1 LASDGSRKRVGQHF-UHFFFAOYSA-N 0.000 claims 1
- PBUPDIAWZXEDNZ-UHFFFAOYSA-N 1-oxo-3-pyridin-3-yl-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinoline-4-carboxylic acid Chemical compound FC(F)(F)CN1C(=O)C2=CC=CC=C2C(C(=O)O)C1C1=CC=CN=C1 PBUPDIAWZXEDNZ-UHFFFAOYSA-N 0.000 claims 1
- SQPWTJARNUDHMP-UHFFFAOYSA-N 2-(2-methylpropyl)-1-oxo-3-(1,2-thiazol-4-yl)-3,4-dihydroisoquinoline-4-carboxylic acid Chemical compound OC(=O)C1C2=CC=CC=C2C(=O)N(CC(C)C)C1C=1C=NSC=1 SQPWTJARNUDHMP-UHFFFAOYSA-N 0.000 claims 1
- WMAVMURGRAZKPX-UHFFFAOYSA-N 2-(2-methylpropyl)-1-oxo-3-(1h-pyrazol-4-yl)-3,4-dihydroisoquinoline-4-carboxylic acid Chemical compound OC(=O)C1C2=CC=CC=C2C(=O)N(CC(C)C)C1C=1C=NNC=1 WMAVMURGRAZKPX-UHFFFAOYSA-N 0.000 claims 1
- XMBLQXVXXZWAGQ-UHFFFAOYSA-N 2-(2-methylpropyl)-1-oxo-3-pyrimidin-5-yl-3,4-dihydroisoquinoline-4-carboxylic acid Chemical compound OC(=O)C1C2=CC=CC=C2C(=O)N(CC(C)C)C1C1=CN=CN=C1 XMBLQXVXXZWAGQ-UHFFFAOYSA-N 0.000 claims 1
- IWWLLORJWHZGTG-UHFFFAOYSA-N 2-(2-methylpropyl)-3-(1-methylpyrazol-4-yl)-1-oxo-3,4-dihydroisoquinoline-4-carboxylic acid Chemical compound OC(=O)C1C2=CC=CC=C2C(=O)N(CC(C)C)C1C=1C=NN(C)C=1 IWWLLORJWHZGTG-UHFFFAOYSA-N 0.000 claims 1
- YRYFQHJZGVZJJN-UHFFFAOYSA-N 2-(cyclopropylmethyl)-1-oxo-3-pyridin-3-yl-3,4-dihydroisoquinoline-4-carboxylic acid Chemical compound O=C1C2=CC=CC=C2C(C(=O)O)C(C=2C=NC=CC=2)N1CC1CC1 YRYFQHJZGVZJJN-UHFFFAOYSA-N 0.000 claims 1
- FYPYNKLSWXBORO-UHFFFAOYSA-N 2-butyl-1-oxo-3-pyridin-3-yl-3,4-dihydroisoquinoline-4-carboxylic acid Chemical compound OC(=O)C1C2=CC=CC=C2C(=O)N(CCCC)C1C1=CC=CN=C1 FYPYNKLSWXBORO-UHFFFAOYSA-N 0.000 claims 1
- YQYMNJMKTNOYQY-UHFFFAOYSA-N 2-butyl-n-(3-cyano-4-fluorophenyl)-1-oxo-3-pyridin-3-yl-3,4-dihydroisoquinoline-4-carboxamide Chemical compound C12=CC=CC=C2C(=O)N(CCCC)C(C=2C=NC=CC=2)C1C(=O)NC1=CC=C(F)C(C#N)=C1 YQYMNJMKTNOYQY-UHFFFAOYSA-N 0.000 claims 1
- JTQUUBROCKVJAP-UHFFFAOYSA-N 3-(1-methylpyrazol-4-yl)-1-oxo-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinoline-4-carboxylic acid Chemical compound C1=NN(C)C=C1C1N(CC(F)(F)F)C(=O)C2=CC=CC=C2C1C(O)=O JTQUUBROCKVJAP-UHFFFAOYSA-N 0.000 claims 1
- LUBUTTBEBGYNJN-UHFFFAOYSA-N 4-amino-n-(5,6-dimethoxypyrimidin-4-yl)benzenesulfonamide;5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1.COC1=NC=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1OC LUBUTTBEBGYNJN-UHFFFAOYSA-N 0.000 claims 1
- MDYLZMIVGWRIOD-UHFFFAOYSA-N 6-fluoro-2-(2-methylpropyl)-3-(1-methylpyrazol-4-yl)-1-oxo-3,4-dihydroisoquinoline-4-carboxylic acid Chemical compound OC(=O)C1C2=CC(F)=CC=C2C(=O)N(CC(C)C)C1C=1C=NN(C)C=1 MDYLZMIVGWRIOD-UHFFFAOYSA-N 0.000 claims 1
- DLYPREQTTOHKSM-UHFFFAOYSA-N 7-chloro-n-[[2-[(dimethylamino)methyl]cyclopenta-1,4-dien-1-yl]methyl]quinolin-4-amine;cyclopenta-1,3-diene;iron(2+) Chemical compound [Fe+2].C1C=CC=[C-]1.C1=[C-]CC(CN(C)C)=C1CNC1=CC=NC2=CC(Cl)=CC=C12 DLYPREQTTOHKSM-UHFFFAOYSA-N 0.000 claims 1
- QVVCPOWOEQAEEU-UHFFFAOYSA-N 7-fluoro-2-(2-methylpropyl)-3-(1-methylpyrazol-4-yl)-1-oxo-3,4-dihydroisoquinoline-4-carboxylic acid Chemical compound OC(=O)C1C2=CC=C(F)C=C2C(=O)N(CC(C)C)C1C=1C=NN(C)C=1 QVVCPOWOEQAEEU-UHFFFAOYSA-N 0.000 claims 1
- AOLYQKXAJPZOQC-UHFFFAOYSA-N 7-fluoro-3-(1-methylpyrazol-4-yl)-1-oxo-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinoline-4-carboxylic acid Chemical class C1=NN(C)C=C1C1N(CC(F)(F)F)C(=O)C2=CC(F)=CC=C2C1C(O)=O AOLYQKXAJPZOQC-UHFFFAOYSA-N 0.000 claims 1
- GBDFOFDXSIDEBM-UHFFFAOYSA-N 7-methoxy-2-(2-methylpropyl)-1-oxo-3-pyridin-3-yl-3,4-dihydroisoquinoline-4-carboxylic acid Chemical class CC(C)CN1C(=O)C2=CC(OC)=CC=C2C(C(O)=O)C1C1=CC=CN=C1 GBDFOFDXSIDEBM-UHFFFAOYSA-N 0.000 claims 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 1
- 235000001258 Cinchona calisaya Nutrition 0.000 claims 1
- LBHLFPGPEGDCJG-UHFFFAOYSA-N N(4)-{2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]quinolin-8-yl}pentane-1,4-diamine Chemical compound COC=1C=C(NC(C)CCCN)C2=NC(OC)=CC(C)=C2C=1OC1=CC=CC(C(F)(F)F)=C1 LBHLFPGPEGDCJG-UHFFFAOYSA-N 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 150000004982 aromatic amines Chemical class 0.000 claims 1
- 229960004191 artemisinin Drugs 0.000 claims 1
- 229930101531 artemisinin Natural products 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 claims 1
- CPPKAGUPTKIMNP-UHFFFAOYSA-N cyanogen fluoride Chemical compound FC#N CPPKAGUPTKIMNP-UHFFFAOYSA-N 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229950010451 ferroquine Drugs 0.000 claims 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 claims 1
- 229960004171 hydroxychloroquine Drugs 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 239000011630 iodine Substances 0.000 claims 1
- 125000002346 iodo group Chemical group I* 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- DYLGFOYVTXJFJP-MYYYXRDXSA-N lumefantrine Chemical compound C12=CC(Cl)=CC=C2C=2C(C(O)CN(CCCC)CCCC)=CC(Cl)=CC=2\C1=C/C1=CC=C(Cl)C=C1 DYLGFOYVTXJFJP-MYYYXRDXSA-N 0.000 claims 1
- 229960004985 lumefantrine Drugs 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 229960001962 mefloquine Drugs 0.000 claims 1
- 229960000901 mepacrine Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- UCRHFBCYFMIWHC-UHFFFAOYSA-N piperaquine Chemical compound ClC1=CC=C2C(N3CCN(CC3)CCCN3CCN(CC3)C=3C4=CC=C(C=C4N=CC=3)Cl)=CC=NC2=C1 UCRHFBCYFMIWHC-UHFFFAOYSA-N 0.000 claims 1
- 229950006717 piperaquine Drugs 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229960005179 primaquine Drugs 0.000 claims 1
- INDBQLZJXZLFIT-UHFFFAOYSA-N primaquine Chemical compound N1=CC=CC2=CC(OC)=CC(NC(C)CCCN)=C21 INDBQLZJXZLFIT-UHFFFAOYSA-N 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 229960005385 proguanil Drugs 0.000 claims 1
- 229960001870 proguanil hydrochloride Drugs 0.000 claims 1
- YFYLPWJKCSESGB-UHFFFAOYSA-N pyronaridine Chemical compound C=12NC(OC)=CC=C2NC2=CC(Cl)=CC=C2C=1N=C(C=C(CN1CCCC1)C1=O)C=C1CN1CCCC1 YFYLPWJKCSESGB-UHFFFAOYSA-N 0.000 claims 1
- 229950011262 pyronaridine Drugs 0.000 claims 1
- GPKJTRJOBQGKQK-UHFFFAOYSA-N quinacrine Chemical compound C1=C(OC)C=C2C(NC(C)CCCN(CC)CC)=C(C=CC(Cl)=C3)C3=NC2=C1 GPKJTRJOBQGKQK-UHFFFAOYSA-N 0.000 claims 1
- 229960000948 quinine Drugs 0.000 claims 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- UGOGIUREIICPLT-UHFFFAOYSA-N spiro[1h-indole-3,1'-pyrido[3,4-b]indole]-2-one Chemical compound C12=NC3=CC=CC=C3C1=CC=NC12C2=CC=CC=C2NC1=O UGOGIUREIICPLT-UHFFFAOYSA-N 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 229950000856 tafenoquine Drugs 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (15)
1. Liječenju koji ima strukturu predstavljenu formulom:
[image]
naznačen time da je Ar1 monociklički heteroaril izabran od 3-piridinila, 4-izoksazolila, N-metil-4-pirazolila, 4-pirazolila, 4-izotiazolila, 5-tiazolila, 5-pirimidinila, i 4-piridazinila; R1 je izabran od vodika, metila, etila, n-propila, i-propila, ciklopropila, n-butila, i-butila, s-butila, t-butila, i ciklobutila i, dopuštajuće valencije, je supstituiran sa 0-3 grupe izabrane od fluora, klora, broma, joda, cijano, metoksila, i etoksila; R2 i R3 su nezavisno izabrane od vodika, C1-C4 alkila, C1-C4 alkoksila, cijano, fluora, klora, broma, i joda; pri čemu supstituenti prstena na atomima ugljika označeni sa oznakama α i β imaju trans konfiguraciju; Ar2 ima strukturu predstavljenu formulom:
[image]
pri čemu su R4a i R4b nezavisno izabrane od vodika, fluora, klora, broma, joda, cijano, C1-C4 alkila, C1-C4 haloalkila, C1-C4 polihaloalkila, C1-C4 alkoksila, C1-C4 haloalkoksila, i C1-C4 polihaloalkoksila; R5 je izabrana od vodika, fluora, klora, broma, joda, cijano, C1-C4 alkila, C1-C4 haloalkila, C1-C4 polihaloalkila, C1-C4 alkoksila, C1-C4 haloalkoksila, i C1-C4 polihaloalkoksila; ili farmaceutski prihvatljive soli, hidrata, solvata ili polimorfa od njih, kao i tautomera, geometrijskih izomera, optički aktivnih oblika od njih kao i tautomera, geometrijskih izomera, optički aktivnih formi od njih, za upotrebu u prevenciji i/ili liječenju malarije.
2. Spoj za upotrebu prema patentnom zahtjevu 1, naznačen time da je R1 izabran od metila, n-propila, i-propila i ciklopropila, opcijski supstituiranih sa 0-3 grupe izabrane od fluora i metoksila.
3. Spoj za upotrebu prema bilo kojem od patentnih zahtjeva od 1 do 2, naznačen time da je R1 izabran od CF3 i (CH3)2CH.
4. Spoj za upotrebu prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time da su R2 i R3 nezavisno izabrane od vodika, C1-C4 alkila, C1-C4 alkoksila, cijano, fluora, klora, broma, i joda.
5. Spoj za upotrebu prema bilo kojem od patentnih zahtjeva od 1 do 4, naznačen time da su R2 i R3 nezavisno izabrane od H, OCH3 i F.
6. Spoj za upotrebu prema bilo kojem od patentnih zahtjeva 1 do 5, naznačen time da su R4a, R4b i R5 nezavisno izabrane od H, CN, F, Cl i OCF3.
7. Spoj za upotrebu prema bilo kojem od patentnih zahtjeva 1 do 6, naznačen time da je Spoj Formule (I) izabran iz sljedeće grupe:
N-(3-cijano-4-fluorofenil)-1-okso-3-(piridin-3-il)-2-(2,2,2-trifluoroetil)-1,2,3,4-tetrahidroizohinolin-4-karboksamid;
N-(3-kloro-5-cijanofenil)-1-okso-3-(piridin-3-il)-2-(2,2,2-trifluoroetil)-1,2,3,4-tetrahidroizohinolin-4-karboksamid;
N-(3-cijanofenil)-1-okso-3-(piridin-3-il)-2-(2,2,2-trifluoroetil)-1,2,3,4-tetrahidroizohinolin-4-karboksamid;
N-(3-cijano-5-fluorofenil)-1-okso-3-(piridin-3-il)-2-(2,2,2-trifluoroetil)-1,2,3,4-tetrahidroizohinolin-4-karboksamid;
1-okso-3-(piridin-3-il)-2-(2,2,2-trifluoroetil)-N-(3-(trifluorometoksi)fenil)-1,2,3,4-tetrahidroizohinolin-4-
karboksamid;
N-(4-fluoro-3-(trifluorometoksi)fenil)-1-okso-3-(piridin-3-il)-2-(2,2,2-trifluoroetil)-1,2,3,4-tetrahidroizohinolin-
4-karboksamid;
N-(3-fluoro-5-(trifluorometoksi)fenil)-1-okso-3-(piridin-3-il)-2-(2,2,2-trifluoroetil)-1,2,3,4-tetrahidroizohinolin-
4-karboksamid;
N-(3-cijano-4-fluorofenil)-2-(ciklopropilmetil)-1-okso-3-(piridin-3-il)-1,2,3,4-tetrahidroizohinolin-4-karboksamid;
N-(3-cijano-5-fluorofenil)-7-fluoro-3-(1-metil-1H-pirazol-4-il)-1-okso-2-(2,2,2-trifluoroetil)-1,2,3,4-tetrahidroizohinolin-4-karboksamid;
N-(3-cijano-4-fluorofenil)-2-izobutil-7-metoksi-1-okso-3-(piridin-3-il)-1,2,3,4-tetrahidroizohinolin-4-karboksamid;
N-(3-cijano-4-fluorofenil)-2-izobutil-1-okso-3-(piridin-3-il)-1,2,3,4-tetrahidroizohinolin-4-karboksamid;
N-(3-hloro-5-cijanofenil)-2-izobutil-1-okso-3-(piridin-3-il)-1,2,3,4-tetrahidroizohinolin-4-karboksamid;
N-(3-cijanofenil)-2-izobutil-1-okso-3-(piridin-3-il)-1,2,3,4-tetrahidroizohinolin-4-karboksamid;
N-(3-cijano-5-fluorofenil)-2-izobutil-1-okso-3-(piridin-3-il)-1,2,3,4-tetrahidroizohinolin-4-karboksamid;
2-izobutil-1-okso-3-(piridin-3-il)-N-(3-(trifluorometoksi)fenil)-1,2,3,4-tetrahidroizohinolin-4-karboksamid;
N-(4-fluoro-3-(trifluorometoksi)fenil)-2-izobutil-1-okso-3-(piridin-3-il)-1,2,3,4-tetrahidroizohinolin-4-karboksamid;
N-(3-fluoro-5-(trifluorometoksi)fenil)-2-izobutil-1-okso-3-(piridin-3-il)-1,2,3,4-tetrahidroizohinolin-4-karboksamid;
N-(3-cijanofenil)-6-fluoro-2-izobutil-3-(1-metil-1H-pirazol-4-il)-1-okso-1,2,3,4-tetrahidroizohinolin-4-
karboksamid;
N-(3-cijano-4-fluorofenil)-3-(1-metil-1H-pirazol-4-il)-1-okso-2-(2,2,2-trifluoroetil)-1,2,3,4-tetrahidroizohinolin-
4-karboksamid;
N-(3-hloro-5-cijanofenil)-3-(1-metil-1H-pirazol-4-il)-1-okso-2-(2,2,2-trifluoroetil)-1,2,3,4-tetrahidroizohinolin-
4-karboksamid;
N-(3-cijanofenil)-3-(1-metil-1H-pirazol-4-il)-1-okso-2-(2,2,2-trifluoroetil)-1,2,3,4-tetrahidroizohinolin-
4-karboksamid;
N-(3-cijano-5-fluorofenil)-3-(1-metil-1H-pirazol-4-il)-1-okso-2-(2,2,2-trifluoroetil)-1,2,3,4-tetrahidroizohinolin-
4-karboksamid;
3-(1-metil-1H-pirazol-4-il)-1-okso-2-(2,2,2-trifluoroetil)-N-(3-(trifluorometoksi)fenil)-1,2,3,4-tetrahidroizohinolin-4-karboksamid;
N-(4-fluoro-3-(trifluorometoksi)fenil)-3-(1-metil-1H-pirazol-4-il)-1-okso-2-(2,2,2-trifluoroetil)-1,2,3,4-tetrahidroizohinolin-4-karboksamid;
N-(3-fluoro-5-(trifluorometoksi)fenil)-3-(1-metil-1H-pirazol-4-il)-1-okso-2-(2,2,2-trifluoroetil)-1,2,3,4-tetrahidroizohinolin-4-karboksamid;
N-(3-cijano-4-fluorofenil)-2-izobutil-3-(1-metil-1H-pirazol-4-il)-1-okso-1,2,3,4-tetrahidroizohinolin-4-
karboksamid;
N-(3-hloro-5-cijanofenil)-2-izobutil-3-(1-metil-1H-pirazol-4-il)-1-okso-1,2,3,4-tetrahidroizohinolin-4-
karboksamid;
N-(3-cijanofenil)-2-izobutil-3-(1-metil-1H-pirazol-4-il)-1-okso-1,2,3,4-tetrahidroizohinolin-4-karboksamid;
N-(3-cijano-5-fluorofenil)-2-izobutil-3-(1-metil-1H-pirazol-4-il)-1-okso-1,2,3,4-tetrahidroizohinolin-4-
karboksamid;
2-izobutil-3-(1-metil-1H-pirazol-4-il)-1-okso-N-(3-(trifluorometoksi)fenil)-1,2,3,4-tetrahidroizohinolin-
4-karboksamid;
N-(4-fluoro-3-(trifluorometoksi)fenil)-2-izobutil-3-(1-metil-1H-pirazol-4-il)-1-okso-1,2,3,4-tetrahidroizohinolin-
4-karboksamid;
N-(3-fluoro-5-(trifluorometoksi)fenil)-2-izobutil-3-(1-metil-1H-pirazol-4-il)-1-okso-1,2,3,4-tetrahidroizohinolin-
4-karboksamid;
N-(3-cijano-5-fluorofenil)-6-fluoro-2-izobutil-3-(1-metil-1H-pirazol-4-il)-1-okso-1,2,3,4-tetrahidroizohinolin-
4-karboksamid;
N-(3-cijano-4-fluorofenil)-1-okso-3-(1H-pirazol-4-il)-2-(2,2,2-trifluoroetil)-1,2,3,4-tetrahidroizohinolin-4-
karboksamid;
N-(3-hloro-5-cijanofenil)-1-okso-3-(1H-pirazol-4-il)-2-(2,2,2-trifluoroetil)-1,2,3,4-tetrahidroizohinolin-
4-karboksamid;
N-(3-cijanofenil)-1-okso-3-(1H-pirazol-4-il)-2-(2,2,2-trifluoroetil)-1,2,3,4-tetrahidroizohinolin-4-karboksamid;
N-(3-cijano-5-fluorofenil)-1-okso-3-(1H-pirazol-4-il)-2-(2,2,2-trifluoroetil)-1,2,3,4-tetrahidroizohinolin-4-
karboksamid;
1-okso-3-(1H-pirazol-4-il)-2-(2,2,2-trifluoroetil)-N-(3-(trifluorometoksi)fenil)-1,2,3,4-tetrahidroizohinolin-
4-karboksamid;
N-(4-fluoro-3-(trifluorometoksi)fenil)-1-okso-3-(1H-pirazol-4-il)-2-(2,2,2-trifluoroetil)-1,2,3,4-tetrahidroizohinolin-4-karboksamid;
N-(3-fluoro-5-(trifluorometoksi)fenil)-1-okso-3-(1H-pirazol-4-il)-2-(2,2,2-trifluoroetil)-1,2,3,4-tetrahidroizohinolin-4-karboksamid;
N-(3-cijano-4-fluorofenil)-7-fluoro-2-izobutil-3-(1-metil-1H-pirazol-4-il)-1-okso-1,2,3,4-tetrahidroizohinolin-
4-karboksamid;
N-(3-cijano-4-fluorofenil)-2-izobutil-1-okso-3-(1H-pirazol-4-il)-1,2,3,4-tetrahidroizohinolin-4-karboksamid;
N-(3-hloro-5-cijanofenil)-2-izobutil-1-okso-3-(1H-pirazol-4-il)-1,2,3,4-tetrahidroizohinolin-4-karboksamid;
N-(3-cijanofenil)-2-izobutil-1-okso-3-(1H-pirazol-4-il)-1,2,3,4-tetrahidroizohinolin-4-karboksamid;
N-(3-cijano-5-fluorofenil)-2-izobutil-1-okso-3-(1H-pirazol-4-il)-1,2,3,4-tetrahidroizohinolin-4-karboksamid;
2-izobutil-1-okso-3-(1H-pirazol-4-il)-N-(3-(trifluorometoksi)fenil)-1,2,3,4-tetrahidroizohinolin-4-karboksamid;
N-(4-fluoro-3-(trifluorometoksi)fenil)-2-izobutil-1-okso-3-(1H-pirazol-4-il)-1,2,3,4-tetrahidroizohinolin-4-
karboksamid;
N-(3-fluoro-5-(trifluorometoksi)fenil)-2-izobutil-1-okso-3-(1H-pirazol-4-il)-1,2,3,4-tetrahidroizohinolin-4-
karboksamid;
N-(3-hloro-5-cijanofenil)-7-fluoro-2-izobutil-3-(1-metil-1H-pirazol-4-il)-1-okso-1,2,3,4-tetrahidroizohinolin-
4-karboksamid;
N-(3-cijano-4-fluorofenil)-2-izobutil-3-(izotiazol-4-il)-1-okso-1,2,3,4-tetrahidroizohinolin-4-karboksamid;
N-(3-cijano-4-fluorofenil)-2-izobutil-1-okso-3-(pirimidin-5-il)-1,2,3,4-tetrahidroizohinolin-4-karboksamid;
i
N-(3-cijano-4-fluorofenil)-1-okso-3-(1H-pirazol-4-il-6,7-difluoro-2-(2,2,2-trifluoroetil)-1,2,3,4-tetrahidroizohinolin-4-karboksamid
8. Spoj koji ima strukturu predstavljenu formulom:
[image]
naznačen time da je Ar1 izabran od 3-piridinila, 4-izoksazolila, N-metil-4-pirazolila, 4-pirazolila, 4-izotiazolila, 5-tiazolila, 5-pirimidinila, i 4-piridazinila; R1 je izabran od CF3 i (CH3)2CH; R2 i R3 su nezavisno izabrani od H, OCH3 i F; Ar2 ima strukturu predstavljenu formulom:
[image]
pri čemu su R4a, R4b i R5 nezavisno izabrane od H, CN, F, Cl i OCF3, ili farmaceutski prihvatljive soli, hidrata, solvata ili polimorfa od njih, kao i tautomera, geometrijskih izomera, optički aktivnih oblika od njih, kao i od tautomera, geometrijskih izomera, optički aktivnih oblika od njih.
9. Spoj prema patentnom zahtjevu 8, naznačen time da je izabran iz sljedeće grupe:
N-(3-cijano-4-fluorofenil)-1-okso-3-(piridin-3-il)-2-(2,2,2-trifluoroetil)-1,2,3,4-tetrahidroizohinolin-4-karboksamid;
N-(3-kloro-5-cijanofenil)-1-okso-3-(piridin-3-il)-2-(2,2,2-trifluoroetil)-1,2,3,4-tetrahidroizohinolin-4-karboksamid;
N-(3-cijanofenil)-1-okso-3-(piridin-3-il)-2-(2,2,2-trifluoroetil)-1,2,3,4-tetrahidroizohinolin-4-karboksamid;
N-(3-cijano-5-fluorofenil)-1-okso-3-(piridin-3-il)-2-(2,2,2-trifluoroetil)-1,2,3,4-tetrahidroizohinolin-4-karboksamid;
1-okso-3-(piridin-3-il)-2-(2,2,2-trifluoroetil)-N-(3-(trifluorometoksi)fenil)-1,2,3,4-tetrahidroizohinolin-4-
karboksamid;
N-(4-fluoro-3-(trifluorometoksi)fenil)-1-okso-3-(piridin-3-il)-2-(2,2,2-trifluoroetil)-1,2,3,4-tetrahidroizohinolin-
4-karboksamid;
N-(3-fluoro-5-(trifluorometoksi)fenil)-1-okso-3-(piridin-3-il)-2-(2,2,2-trifluoroetil)-1,2,3,4-tetrahidroizohinolin-
4-karboksamid;
N-(3-cijano-4-fluorofenil)-2-(ciklopropilmetil)-1-okso-3-(piridin-3-il)-1,2,3,4-tetrahidroizohinolin-4-karboksamid;
N-(3-cijano-5-fluorofenil)-7-fluoro-3-(1-metil-1H-pirazol-4-il)-1-okso-2-(2,2,2-trifluoroetil)-1,2,3,4-tetrahidroizohinolin-4-karboksamid;
N-(3-cijano-4-fluorofenil)-2-izobutil-7-metoksi-1-okso-3-(piridin-3-il)-1,2,3,4-tetrahidroizohinolin-4-karboksamid;
N-(3-cijano-4-fluorofenil)-2-izobutil-1-okso-3-(piridin-3-il)-1,2,3,4-tetrahidroizohinolin-4-karboksamid;
N-(3-hloro-5-cijanofenil)-2-izobutil-1-okso-3-(piridin-3-il)-1,2,3,4-tetrahidroizohinolin-4-karboksamid;
N-(3-cijanofenil)-2-izobutil-1-okso-3-(piridin-3-il)-1,2,3,4-tetrahidroizohinolin-4-karboksamid;
N-(3-cijano-5-fluorofenil)-2-izobutil-1-okso-3-(piridin-3-il)-1,2,3,4-tetrahidroizohinolin-4-karboksamid;
2-izobutil-1-okso-3-(piridin-3-il)-N-(3-(trifluorometoksi)fenil)-1,2,3,4-tetrahidroizohinolin-4-karboksamid;
N-(4-fluoro-3-(trifluorometoksi)fenil)-2-izobutil-1-okso-3-(piridin-3-il)-1,2,3,4-tetrahidroizohinolin-4-karboksamid;
N-(3-fluoro-5-(trifluorometoksi)fenil)-2-izobutil-1-okso-3-(piridin-3-il)-1,2,3,4-tetrahidroizohinolin-4-karboksamid;
N-(3-cijanofenil)-6-fluoro-2-izobutil-3-(1-metil-1H-pirazol-4-il)-1-okso-1,2,3,4-tetrahidroizohinolin-4-
karboksamid;
N-(3-cijano-4-fluorofenil)-3-(1-metil-1H-pirazol-4-il)-1-okso-2-(2,2,2-trifluoroetil)-1,2,3,4-tetrahidroizohinolin-
4-karboksamid;
N-(3-hloro-5-cijanofenil)-3-(1-metil-1H-pirazol-4-il)-1-okso-2-(2,2,2-trifluoroetil)-1,2,3,4-tetrahidroizohinolin-
4-karboksamid;
N-(3-cijanofenil)-3-(1-metil-1H-pirazol-4-il)-1-okso-2-(2,2,2-trifluoroetil)-1,2,3,4-tetrahidroizohinolin-
4-karboksamid;
N-(3-cijano-5-fluorofenil)-3-(1-metil-1H-pirazol-4-il)-1-okso-2-(2,2,2-trifluoroetil)-1,2,3,4-tetrahidroizohinolin-
4-karboksamid;
3-(1-metil-1H-pirazol-4-il)-1-okso-2-(2,2,2-trifluoroetil)-N-(3-(trifluorometoksi)fenil)-1,2,3,4-tetrahidroizohinolin-4-karboksamid;
N-(4-fluoro-3-(trifluorometoksi)fenil)-3-(1-metil-1H-pirazol-4-il)-1-okso-2-(2,2,2-trifluoroetil)-1,2,3,4-tetrahidroizohinolin-4-karboksamid;
N-(3-fluoro-5-(trifluorometoksi)fenil)-3-(1-metil-1H-pirazol-4-il)-1-okso-2-(2,2,2-trifluoroetil)-1,2,3,4-tetrahidroizohinolin-4-karboksamid;
2-butil-N-(3-cijano-4-fluorofenil)-1-okso-3-(piridin-3-il)-1,2,3,4-tetrahidroizohinolin-4-karboksamid;
N-(3-cijano-4-fluorofenil)-2-izobutil-3-(1-metil-1H-pirazol-4-il)-1-okso-1,2,3,4-tetrahidroizohinolin-4-
karboksamid;
N-(3-hloro-5-cijanofenil)-2-izobutil-3-(1-metil-1H-pirazol-4-il)-1-okso-1,2,3,4-tetrahidroizohiinolin-4-
karboksamid;
N-(3-cijanofenil)-2-izobutil-3-(1-metil-1H-pirazol-4-il)-1-okso-1,2,3,4-tetrahidroizohinolin-4-karboksamid;
N-(3-cijano-5-fluorofenil)-2-izobutil-3-(1-metil-1H-pirazol-4-il)-1-okso-1,2,3,4-tetrahidroizohiinolin-4-
karboksamid;
2-izobutil-3-(1-metil-1H-pirazol-4-il)-1-okso-N-(3-(trifluorometoksi)fenil)-1,2,3,4-tetrahidroizohinolin-
4-karboksamid;
N-(4-fluoro-3-(trifluorometoksi)fenil)-2-izobutil-3-(1-metil-1H-pirazol-4-il)-1-okso-1,2,3,4-tetrahidroizohinolin-
4-karboksamid;
N-(3-fluoro-5-(trifluorometoksi)fenil)-2-izobutil-3-(1-metil-1H-pirazol-4-il)-1-okso-1,2,3,4-tetrahidroizohinolin-
4-karboksamid;
N-(3-cijano-5-fluorofenil)-6-fluoro-2-izobutil-3-(1-metil-1H-pirazol-4-il)-1-okso-1,2,3,4-tetrahidroizohinolin-
4-karboksamid;
N-(3-cijano-4-fluorofenil)-1-okso-3-(1H-pirazol-4-il)-2-(2,2,2-trifluoroetil)-1,2,3,4-tetrahidroizohinolin-4-
karboksamid;
N-(3-hloro-5-cijanofenil)-1-okso-3-(1H-pirazol-4-il)-2-(2,2,2-trifluoroetil)-1,2,3,4-tetrahidroizohinolin-
4-karboksamid;
N-(3-cijanofenil)-1-okso-3-(1H-pirazol-4-il)-2-(2,2,2-trifluoroetil)-1,2,3,4-tetrahidroizohinolin-4-karboksamid;
N-(3-cijano-5-fluorofenil)-1-okso-3-(1H-pirazol-4-il)-2-(2,2,2-trifluoroetil)-1,2,3,4-tetrahidroizohinolin-4-
karboksamid;
1-okso-3-(1H-pirazol-4-il)-2-(2,2,2-trifluoroetil)-N-(3-(trifluorometoksi)fenil)-1,2,3,4-tetrahidroizohinolin-
4-karboksamid;
N-(4-fluoro-3-(trifluorometoksi)fenil)-1-okso-3-(1H-pirazol-4-il)-2-(2,2,2-trifluoroetil)-1,2,3,4-tetrahidroizohinolin-4-karboksamid;
N-(3-fluoro-5-(trifluorometoksi)fenil)-1-okso-3-(1H-pirazol-4-il)-2-(2,2,2-trifluoroetil)-1,2,3,4-tetrahidroizohinolin-4-karboksamid;
N-(3-cijano-4-fluorofenil)-7-fluoro-2-izobutil-3-(1-metil-1H-pirazol-4-il)-1-okso-1,2,3,4-tetrahidroizohinolin-
4-karboksamid;
N-(3-cijano-4-fluorofenil)-2-izobutil-1-okso-3-(1H-pirazol-4-il)-1,2,3,4-tetrahidroizohinolin-4-karboksamid;
N-(3-hloro-5-cijanofenil)-2-izobutil-1-okso-3-(1H-pirazol-4-il)-1,2,3,4-tetrahidroizohinolin-4-karboksamid;
N-(3-cijanofenil)-2-izobutil-1-okso-3-(1H-pirazol-4-il)-1,2,3,4-tetrahidroizohinolin-4-karboksamid;
N-(3-cijano-5-fluorofenil)-2-izobutil-1-okso-3-(1H-pirazol-4-il)-1,2,3,4-tetrahidroizohinolin-4-karboksamid;
2-izobutil-1-okso-3-(1H-pirazol-4-il)-N-(3-(trifluorometoksi)fenil)-1,2,3,4-tetrahidroizohinolin-4-karboksamid;
N-(4-fluoro-3-(trifluorometoksi)fenil)-2-izobutil-1-okso-3-(1H-pirazol-4-il)-1,2,3,4-tetrahidroizohinolin-4-
karboksamid;
N-(3-fluoro-5-(trifluorometoksi)fenil)-2-izobutil-1-okso-3-(1H-pirazol-4-il)-1,2,3,4-tetrahidroizohinolin-4-
karboksamid;
N-(3-hloro-5-cijanofenil)-7-fluoro-2-izobutil-3-(1-metil-1H-pirazol-4-il)-1-okso-1,2,3,4-tetrahidroizohinolin-
4-karboksamid;
N-(3-cijano-4-fluorofenil)-2-izobutil-3-(izotiazol-4-il)-1-okso-1,2,3,4-tetrahidroizohinolin-4-karboksamid;
N-(3-cijano-4-fluorofenil)-2-izobutil-1-okso-3-(pirimidin-5-il)-1,2,3,4-tetrahidroizohinolin-4-karboksamid;
IN-(3-cijano-4-fluorofenil)-1-okso-3-(1H-pirazol-4-il-6,7-difluoro-2-(2,2,2-trifluoroetil)-1,2,3,4-tetrahidroizohinolin-4-karboksamid.
10. Spoj prema patentnim zahtjevima 8 ili 9, naznačen time da je za upotrebu kao lijek.
11. Farmaceutski pripravak naznačen time da sadrži najmanje jedan spoj prema patentnom zahtjevu 8 ili 9 i farmaceutski prihvatljiv nosač, otapalo ili ekscipijens od njih.
12. Farmaceutski pripravak naznačen time da sadrži najmanje jedan spoj prema patentnom zahtjevu 8 ili 9, dalje sadržavajući najmanje još jedan dodatni antimalarijski agens.
13. Farmaceutski pripravak prema patentnom zahtjevu 12 naznačen time da je dalje navedeni antimalarijski agens izbran od artemisinina ili derivata artemisinina, klorokvina, meflokvina, kinina, atovaksona/proguanila, doksiciklina, hidroksiklorokvina, pironaridina, lumefantrina, pirimetamin-sulfadoksina, kvinakrina, klorokvina, primakvina, doksiciklina, atovaksona i proguanil hidroklorida, piperakvina, ferokvina, tafenokvina, arterolana, spiro[3H-indol-3,1’-[1H]pirido[3,4-b]indol]-2(1H)-on (CAS Registarski broj:1193314-23-6), 5,7’-dihloro-6’-fluoro-2’,3’,4’,9’-tetrahidro-3’-metil-,(1’R,3’S)-], Sumpor [4-[[2-(1,1-difluoroetil)-5-metil[1,2,4]triazolo[1,5-a]pirimidin-7-il]amino]fenil]pentafluoro-] (CAS Registarski broj: 1282041-94-4), Morfolin, ili 4-[2-(4-cis-dispiro[cikloheksan-1,3’-[1,2,4]trioksolan-5’,2"-triciklo [3.3.1.13,7]dekan]-4-ilfenoksi)etil]-] (CAS Registarski broj:1029939-86-3).
14. Proces za dobivanje spoja Formule (II) naznačen time da je Ar1 izabran od 3-piridinila, 4-(1-metilpirazolila) i 4-pirazolila; R1 je izabrana od CF3, propila, ciklopropila i (CH3)2CH; R2 i R3 su nezavisno izabrane od H, OCH3 i F; R5a, R5b i R6 su nezavisno izabrane od H, CN, F, Cl i OCF3, sadržavajući korak reagiranja karboksilne kiseline formule 2a pri čemu je Ar1 izabran od 3-piridinila, 4-(1-metilpirazolila) i 4-pirazolila ; R1 je izabrana od CF3, propila, ciklopropila i (CH3)2CH; R2 i R3 su nezavisno izabrani od H, OCH3 i F sa aril aminom formule 3a pri čemu su R4a, R4b i R nezavisno izabrane od H, CN, F, Cl i OCF3:
[image]
15. Intermedijar formule 2a
[image]
naznačen time da je izabran od 3-piridinila, 4-(1-metilpirazolila) i 4-pirazolila; R1 je izabran od CF3, propila, ciklopropila i (CH3)2CH; R2 i R3 su nezavisno izabrane od H, OCH3 i F; i R5a, R5b i R6 su nezavisno izabrane od H, CN, F, Cl i OCF3 izabran od sljedeće grupe:
1-okso-2-izobutil-3-(1H-pirazol-4-il)-1,2,3,4-tetrahidroizohinolin-4- karboksilne kiseline;
1-okso-2-(2,2,2-trifluoroetil)-3-(1H-pirazol-4-il)-1,2,3,4-tetrahidroizohinolin-4-karboksilne kiseline;
1-okso-2-izobutil-3-(1-metil-1H-pirazol-4-il)-1,2,3,4-tetrahidroizohinolin-4-karboksilne kiseline;
1-okso-2-(2,2,2-trifluoroetil)-3-(1-metil-1H-pirazol-4-il)-1,2,3,4-tetrahidroizohinolin-4-karboksilne kiseline;
1-okso-2-(2,2,2-trifluoroetil)-3-(piridin-3-il)-1,2,3,4-tetrahidroizohinolin-4-karboksilne kiseline;
1-okso-2-(ciklopropilmetil)-3-(piridin-3-il)-1,2,3,4-tetrahidroizohinolin-4-karboksilne kiseline;
1-okso-2-(1-butil)-3-(piridin-3-il)-1,2,3,4-tetrahidroizohinolin-4-karboksilne kiseline;
1-okso-2-izobutil-3-(1-metil-1H-pirazol-4-il)-7-fluoro-1,2,3,4-tetrahidroizohinolin-4-karboksilne kiseline;
1-okso-2-izobutil-3-(1-metil-1H-pirazol-4-il)-6-fluoro-1,2,3,4-tetrahidroizohinolin-4-karboksilne kiseline;
1-okso-2-izobutil-3-(izotiazol-4-il)-1,2,3,4-tetrahidroizohinolin-4-karboksilne kiseline;
1-okso-2-izobutil-3-(pirimidin-5-il)-1,2,3,4-tetrahidroizohinolin-4-karboksilne kiseline;
1-okso-2-(2,2,2-trifluoroetil)-3-(1-metil-1H-pirazol-4-il)-7-fluoro-1,2,3,4-tetrahidroizohinolin-4- karboksilne kiseline;
I 2-izobutil-7-metoksi-1-okso-3-(piridin-3-il)-1,2,3,4-tetrahidroizohinolin-4-karboksilne kiseline.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161527594P | 2011-08-25 | 2011-08-25 | |
PCT/IB2012/054305 WO2013027196A1 (en) | 2011-08-25 | 2012-08-24 | Substituted 2-alkyl-1-oxo-n-phenyl-3-heteroaryl-1,2,3,4- tetrahydroisoquinoline-4-carboxamides for antimalarial therapies |
EP12772470.6A EP2748147B1 (en) | 2011-08-25 | 2012-08-24 | Substituted 2-alkyl-1-oxo-n-phenyl-3-heteroaryl-1,2,3,4-tetrahydroisoquinoline-4-carboxamides for antimalarial therapies |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20171567T1 true HRP20171567T1 (hr) | 2017-11-17 |
Family
ID=47018313
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20171567TT HRP20171567T1 (hr) | 2011-08-25 | 2017-10-16 | Supstituirani 2-alkil-1-okso-n-fenil-3-heteroaril-1,2,3,4-tetrahidroizohinolin-4-karboksamidi za antimalarijske terapije |
Country Status (19)
Country | Link |
---|---|
US (1) | US9416124B2 (hr) |
EP (1) | EP2748147B1 (hr) |
JP (1) | JP6035334B2 (hr) |
CN (1) | CN103930404B (hr) |
BR (1) | BR112014004437B1 (hr) |
CA (1) | CA2846507C (hr) |
CY (1) | CY1119748T1 (hr) |
DK (1) | DK2748147T3 (hr) |
ES (1) | ES2644082T3 (hr) |
HK (1) | HK1199443A1 (hr) |
HR (1) | HRP20171567T1 (hr) |
HU (1) | HUE034721T2 (hr) |
LT (1) | LT2748147T (hr) |
ME (1) | ME02908B (hr) |
PL (1) | PL2748147T3 (hr) |
PT (1) | PT2748147T (hr) |
RS (1) | RS56544B1 (hr) |
SI (1) | SI2748147T1 (hr) |
WO (1) | WO2013027196A1 (hr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200134203A (ko) * | 2017-08-21 | 2020-12-01 | 나비젠, 인코포레이티드 | Arf6 억제제 및 관련 방법 |
EP3892332A1 (en) | 2020-04-09 | 2021-10-13 | University Of Kentucky Research Foundation | New anti-malarial agents |
JP2024515336A (ja) | 2021-04-15 | 2024-04-08 | アールディーピー ファーマ アーゲー | 抗ウイルス剤及び抗腫瘍剤として使用するためのイソキノリン誘導体 |
EP4074314A1 (en) * | 2021-04-15 | 2022-10-19 | Valdospan GmbH | Isoquinoline derivatives for use as antiviral and antitumour agents |
WO2024083802A1 (en) | 2022-10-17 | 2024-04-25 | Valdospan Gmbh | Isoquinoline derivatives as protein degraders, e7 degraders, antivirals, tumor therapeutics and immune suppressives |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5639761A (en) * | 1994-02-14 | 1997-06-17 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Antimalarial naphthylisoquinoline alkaloids and pharmaceutical compositions and medical uses thereof |
US5409938A (en) * | 1994-02-14 | 1995-04-25 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Antimalarial korupensamines and pharmaceutical compositions and medical uses thereof |
US6921762B2 (en) * | 2001-11-16 | 2005-07-26 | Amgen Inc. | Substituted indolizine-like compounds and methods of use |
WO2004004727A1 (en) * | 2002-07-03 | 2004-01-15 | Axys Pharmaceuticals, Inc. | 3,4-dihydroisoquinolin-1-one derivatives as inducers of apoptosis |
DE10237722A1 (de) | 2002-08-17 | 2004-08-19 | Aventis Pharma Deutschland Gmbh | Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase |
DE10312963A1 (de) | 2003-03-24 | 2004-10-07 | Aventis Pharma Deutschland Gmbh | Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament |
PE20100737A1 (es) * | 2005-03-25 | 2010-11-27 | Glaxo Group Ltd | Nuevos compuestos |
RU2302417C1 (ru) | 2006-03-14 | 2007-07-10 | Иващенко Андрей Александрович | 1-оксо-3-(1н-индол-3-ил)-1,2,3,4-тетрагидроизохинолины, способы их получения, комбинаторная библиотека и фокусированная библиотека |
US20110281869A1 (en) * | 2008-05-19 | 2011-11-17 | Hamed Aissaoui | Tetrahydroisoquinolines as antimalarial agents |
GB0820856D0 (en) | 2008-11-14 | 2008-12-24 | Univ Leuven Kath | Novel inhibitors of flavivirus replication |
-
2012
- 2012-08-24 ME MEP-2017-250A patent/ME02908B/me unknown
- 2012-08-24 ES ES12772470.6T patent/ES2644082T3/es active Active
- 2012-08-24 RS RS20171090A patent/RS56544B1/sr unknown
- 2012-08-24 WO PCT/IB2012/054305 patent/WO2013027196A1/en active Application Filing
- 2012-08-24 CA CA2846507A patent/CA2846507C/en active Active
- 2012-08-24 CN CN201280041436.4A patent/CN103930404B/zh active Active
- 2012-08-24 BR BR112014004437-6A patent/BR112014004437B1/pt active IP Right Grant
- 2012-08-24 LT LTEP12772470.6T patent/LT2748147T/lt unknown
- 2012-08-24 PT PT127724706T patent/PT2748147T/pt unknown
- 2012-08-24 PL PL12772470T patent/PL2748147T3/pl unknown
- 2012-08-24 JP JP2014526594A patent/JP6035334B2/ja active Active
- 2012-08-24 HU HUE12772470A patent/HUE034721T2/hu unknown
- 2012-08-24 US US14/240,994 patent/US9416124B2/en active Active
- 2012-08-24 DK DK12772470.6T patent/DK2748147T3/da active
- 2012-08-24 SI SI201231080T patent/SI2748147T1/sl unknown
- 2012-08-24 EP EP12772470.6A patent/EP2748147B1/en active Active
-
2014
- 2014-12-24 HK HK14112913.3A patent/HK1199443A1/xx not_active IP Right Cessation
-
2017
- 2017-10-16 HR HRP20171567TT patent/HRP20171567T1/hr unknown
- 2017-10-20 CY CY20171101092T patent/CY1119748T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP2748147A1 (en) | 2014-07-02 |
RS56544B1 (sr) | 2018-02-28 |
US9416124B2 (en) | 2016-08-16 |
PT2748147T (pt) | 2017-11-14 |
CN103930404B (zh) | 2016-08-24 |
WO2013027196A1 (en) | 2013-02-28 |
US20140235593A1 (en) | 2014-08-21 |
BR112014004437A8 (pt) | 2018-01-23 |
LT2748147T (lt) | 2017-10-25 |
JP2014524464A (ja) | 2014-09-22 |
EP2748147B1 (en) | 2017-08-02 |
CA2846507A1 (en) | 2013-02-28 |
BR112014004437A2 (pt) | 2017-03-28 |
PL2748147T3 (pl) | 2018-01-31 |
HK1199443A1 (en) | 2015-07-03 |
CA2846507C (en) | 2020-03-10 |
CY1119748T1 (el) | 2018-06-27 |
ES2644082T3 (es) | 2017-11-27 |
ME02908B (me) | 2018-10-20 |
CN103930404A (zh) | 2014-07-16 |
BR112014004437B1 (pt) | 2021-12-14 |
HUE034721T2 (hu) | 2018-02-28 |
JP6035334B2 (ja) | 2016-11-30 |
WO2013027196A9 (en) | 2013-04-18 |
SI2748147T1 (sl) | 2017-11-30 |
DK2748147T3 (da) | 2017-11-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20171567T1 (hr) | Supstituirani 2-alkil-1-okso-n-fenil-3-heteroaril-1,2,3,4-tetrahidroizohinolin-4-karboksamidi za antimalarijske terapije | |
CA2647116C (en) | Imidazo [1, 2-b] pyridazines, their processes of preparation and their use as gaba receptor ligands | |
JP6236068B2 (ja) | RORγ活性を阻害し疾患を治療するためのテトラヒドロナフチリジンおよび関連二環式化合物 | |
AU2012382875B2 (en) | Compound as WNT signaling inhibitor, composition, and use thereof | |
RU2240322C2 (ru) | Производные нафтиридина и содержащая их фармацевтическая композиция | |
CA2989722C (en) | Pyrazolo[1,5-a]triazin-4-amine derivatives useful in therapy | |
HRP20160396T1 (hr) | Novi kiralni n-acil-5,6,7(8-susupstituirani)-tetrahidro-/1,2,4/triazolo/4,3-a/pirazini kao selektivni nk-3 receptor antagonisti, farmaceutski pripravak, i metode za upor | |
RU2015149528A (ru) | 2-фенилимидазо[1,2-а]пиримидины в качестве визуализирующих средств | |
JP2014037426A5 (hr) | ||
JP2014514360A5 (hr) | ||
HRP20170695T1 (hr) | Fenil-3-aza-biciklo[3.1.0]heks-3-il-metanoni i njihova uporaba u obliku lijeka | |
CA2395717C (en) | Fused imidazolium derivatives | |
RU2010117156A (ru) | Гетероциклические соединения в качестве антагонистов crth2 рецептора | |
JP6893516B2 (ja) | 3−((ヘテロ−)アリール)−8−アミノ−2−オキソ−1,3−ジアザ−スピロ−[4.5]−デカン誘導体 | |
KR100820006B1 (ko) | 헤테로사이클릭 gaba-a 아형 선택적 수용체 조절제 | |
JP2014524464A5 (hr) | ||
ES2650921T3 (es) | Compuestos tricíclicos de imidazol como inhibidores de hidroxilasa de triptófano | |
HRP20170773T1 (hr) | Novi anti-malarijski agensi | |
US7943611B2 (en) | Imidazo[1,2-A]pyridin-3-yl-acetic acid hydrazides, processes, for their preparation and pharmaceutical uses thereof | |
TW202039446A (zh) | 雜環化合物 | |
RU2014127984A (ru) | Хинолиновые производные как ингибиторы фермента pde10a | |
JPWO2021001453A5 (hr) | ||
JP2023551186A (ja) | B型肝炎ウイルス(hbv)感染症の処置及び予防のための2-フェニルベンゾトリアゾール-5-アミン誘導体 | |
JPWO2021204952A5 (hr) |